The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Early evidence suggests BPC 157 repairs tissue rather than just dulling symptoms. To read more, tap the link in bio. BPC 157 FDA Approval Unlikely Due to Patent Economics Stefano M. Sinicropi, MD posted on the topic LinkedIn Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law